Login to Your Account



Elan Plans to Assemble a 'Constellation' of Transactions


Wednesday, May 1, 2013
DUBLIN, Ireland – Two days after the board of Elan Corp. plc unanimously rejected Royalty Pharma's $7.3 billion takeover offer, CEO Kelly Martin set out, as best he could, the contours of the company's M&A strategy during a first-quarter results call with analysts last week.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription